A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.
PTCL
DRUG: YY-20394 treatment
ORR, Objective Response Rate, up to 12 months
DOR, Duration of response, up to 12 months|PFS, Progression free survival, up to 12 months|DCR, Disease control rate, up to 12 months|TTR, Time to response, up to 12 months|Safety and Tolerability, safety and tolerability of investigational Product assessed as the number of participants experiencing adverse events (AEs, CTCAE5.0) or abnormalities in vital signs, laboratory tests, or electrocardiograms., up to 12 months
A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.